May 17, 2022 / 02:30PM GMT
Brian Corey Abrahams - RBC Capital Markets, Research Division - Senior Biotechnology Analyst
All right. Good morning, everyone. I'm Brian Abrahams, one of the senior biotech analysts at RBC Capital Markets, and thanks for joining us. Really pleased to have our next featured company Incyte, represented by their Chief Medical Officer, Steven Stein; and their Chief Financial Officer, Christiana Stamoulis. So thanks again for being here, and it's great to see you guys in person.
Christiana Stamoulis - Incyte Corporation - Executive VP & CFO
Thank you for having us.
Questions and Answers:
Brian Corey Abrahams - RBC Capital Markets, Research Division - Senior Biotechnology AnalystGreat. So I know there's a lot going on at Incyte, a lot to talk about, but we probably get the most questions these days on the OPZELURA launch. So maybe we can start with that. And maybe if you could just start broadly on how the launch is going. Where you're seeing the drug fitting into the atopic derm treatment paradigm, how docs are
Trustpilot
